Genetic Variants in Epidermal Growth Factor Receptor Pathway Genes and Risk of Esophageal Squamous Cell Carcinoma and Gastric Cancer in a Chinese Population

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Li, Wen Qing ^a   Hu, Nan ^a   Wang, Zhaoming ^a,b   Yu, Kai ^a   Su, Hua ^a   Wang, Lemin ^a   Wang, Chaoyu ^a   Chanock, Stephen J ^b   Burdett, Laurie ^b   Ding, Ti ^c   Qiao, You Lin ^d   Fan, Jin Hu ^d   Wang, Yuan ^c   Xu, Yi ^c   Giffen, Carol ^e   Xiong, Xiaoqin ^e   Murphy, Gwen ^a   Tucker, Margaret A ^a   Dawsey, Sanford M ^a   Freedman, Neal D ^a   Abnet, Christian C ^a   Goldstein, Alisa M ^a   Taylor, Philip R ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c SHANXI CANCER HOSPITAL   (China)

^d PEKING UNION MEDICAL COLLEGE   (China)

^e INFORMATION MANAGEMENT SERVICES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; ARTICLE; CANCER RISK; CHINESE; CHRNE GENE; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FYN GENE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GNAI3 GENE; HUMAN; ITCH GENE; MAJOR CLINICAL STUDY; MAP2K1 GENE; MAP2K4 GENE; MAPK8 GENE; PAK4 GENE; PIK3R3 GENE; PLCG2 GENE; PRLR GENE; RPS6KB2 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TLN1 GENE; TUMOR GENE; WASL GENE;

ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; CHINA; ESOPHAGEAL NEOPLASMS; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84880435102     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068999     Document Type: Article

References (41)

1. Hynes NE, Lane HA, (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354.
2. Citri A, Yarden Y, (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7: 505-516.
3. Krause DS, Van Etten RA, (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353: 172-187.
4. Okines A, Cunningham D, Chau I, (2011) Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol 8: 492-503.
5. Baselga J, Swain SM, (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9: 463-475.
6. Dulak AM, Schumacher SE, van Lieshout J, Imamura Y, Fox C, et al. (2012) Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res 72: 4383-4393.
7. Deng N, Goh LK, Wang H, Das K, Tao J, et al. (2012) A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61: 673-684.
8. Corso G, Velho S, Paredes J, Pedrazzani C, Martins D, et al. (2011) Oncogenic mutations in gastric cancer with microsatellite instability. Eur J Cancer 47: 443-451.
9. Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, et al. (2006) Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 12: 4283-4287.
10. Lee JW, Soung YH, Seo SH, Kim SY, Park CH, et al. (2006) Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res 12: 57-61.
11. Soung YH, Lee JW, Kim SY, Wang YP, Jo KH, et al. (2006) Somatic mutations of the ERBB4 kinase domain in human cancers. Int J Cancer 118: 1426-1429.
12. Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, et al. (2012) Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 44: 570-574.
13. Paterson AL, Shannon NB, Lao-Sirieix P, Ong CA, Peters CJ, et al. (2012) A systematic approach to therapeutic target selection in oesophago-gastric cancer. Gut. [Epub ahead of print].
14. Ma S, Bao JY, Kwan PS, Chan YP, Tong CM, et al. (2012) Identification of PTK6, via RNA sequencing analysis, as a suppressor of esophageal squamous cell carcinoma. Gastroenterology 143: 675-686 e671-612.
15. Yang JJ, Cho LY, Ma SH, Ko KP, Shin A, et al. (2011) Oncogenic CagA promotes gastric cancer risk via activating ERK signaling pathways: a nested case-control study. PLoS One 6: e21155.
16. Menke V, Pot RG, Moons LM, van Zoest KP, Hansen B, et al. (2012) Functional single-nucleotide polymorphism of epidermal growth factor is associated with the development of Barrett's esophagus and esophageal adenocarcinoma. J Hum Genet 57: 26-32.
17. Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, et al. (2006) MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 24: 4434-4440.
18. Hong Y, Miao X, Zhang X, Ding F, Luo A, et al. (2005) The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 65: 9582-9587.
19. Cescon DW, Bradbury PA, Asomaning K, Hopkins J, Zhai R, et al. (2009) p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis. Clin Cancer Res 15: 3103-3109.
20. Ma J, Zhang J, Ning T, Chen Z, Xu C, (2012) Association of genetic polymorphisms in MDM2, PTEN and P53 with risk of esophageal squamous cell carcinoma. J Hum Genet 57: 261-264.
21. Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, et al. (2009) Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 27: 857-871.
22. Lanuti M, Liu G, Goodwin JM, Zhai R, Fuchs BC, et al. (2008) A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome. Clin Cancer Res 14: 3216-3222.
23. Dong LM, Potter JD, White E, Ulrich CM, Cardon LR, et al. (2008) Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA 299: 2423-2436.
24. Abnet CC, Freedman ND, Hu N, Wang Z, Yu K, et al. (2010) A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. Nat Genet 42: 764-767.
25. Sakamoto H, Yoshimura K, Saeki N, Katai H, Shimoda T, et al. (2008) Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet 40: 730-740.
26. Shi Y, Hu Z, Wu C, Dai J, Li H, et al. (2011) A genome-wide association study identifies new susceptibility loci for non-cardia gastric cancer at 3q13.31 and 5p13.1. Nat Genet 43: 1215-1218.
27. Wang LD, Zhou FY, Li XM, Sun LD, Song X, et al. (2010) Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54. Nat Genet 42: 759-763.
28. Wu C, Hu Z, He Z, Jia W, Wang F, et al. (2011) Genome-wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations. Nat Genet 43: 679-684.
29. Abnet CC, Wang Z, Song X, Hu N, Zhou FY, et al. (2012) Genotypic variants at 2q33 and risk of esophageal squamous cell carcinoma in China: a meta-analysis of genome-wide association studies. Hum Mol Genet 21: 2132-2141.
30. Tanaka F, Yamamoto K, Suzuki S, Inoue H, Tsurumaru M, et al. (2010) Strong interaction between the effects of alcohol consumption and smoking on oesophageal squamous cell carcinoma among individuals with ADH1B and/or ALDH2 risk alleles. Gut 59: 1457-1464.
31. Cui R, Kamatani Y, Takahashi A, Usami M, Hosono N, et al. (2009) Functional variants in ADH1B and ALDH2 coupled with alcohol and smoking synergistically enhance esophageal cancer risk. Gastroenterology 137: 1768-1775.
32. Wu C, Kraft P, Zhai K, Chang J, Wang Z, et al. (2012) Genome-wide association analyses of esophageal squamous cell carcinoma in Chinese identify multiple susceptibility loci and gene-environment interactions. Nat Genet 44: 1090-1097.
33. Wang K, Li M, Hakonarson H, (2010) Analysing biological pathways in genome-wide association studies. Nat Rev Genet 11: 843-854.
34. Yu K, Li Q, Bergen AW, Pfeiffer RM, Rosenberg PS, et al. (2009) Pathway analysis by adaptive combination of P-values. Genet Epidemiol 33: 700-709.
35. Gao Y, Hu N, Han XY, Ding T, Giffen C, et al. (2011) Risk factors for esophageal and gastric cancers in Shanxi Province, China: a case-control study. Cancer Epidemiol 35: e91-99.
36. Qiao YL, Dawsey SM, Kamangar F, Fan JH, Abnet CC, et al. (2009) Total and Cancer Mortality After Supplementation With Vitamins and Minerals: Follow-up of the Linxian General Population Nutrition Intervention Trial. J Natl Cancer Inst 101: 507-518.
37. Eguchi R, Kubo S, Takeda H, Ohta T, Tabata C, et al. (2012) Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells. Carcinogenesis 33: 969-975.
38. Slattery ML, Lundgreen A, Wolff RK, (2012) MAP kinase genes and colon and rectal cancer. Carcinogenesis 33: 2398-2408.
39. Li D, Duell EJ, Yu K, Risch HA, Olson SH, et al. (2012) Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility factors for pancreatic cancer. Carcinogenesis 33: 1384-1390.
40. Ma JL, Zhang L, Brown LM, Li JY, Shen L, et al. (2012) Fifteen-year effects of Helicobacter pylori,garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst 104: 488-492.
41. Michel A, Waterboer T, Kist M, Pawlita M, (2009) Helicobacter pylori multiplex serology. Helicobacter 14: 525-535.